• SPX
  • $5,782.76
  • 1.23 %
  • $70.07
  • DJI
  • $42,221.88
  • 1.02 %
  • $427.28
  • N225
  • $39,007.45
  • 1.38 %
  • $532.77
  • FTSE
  • $8,172.39
  • -0.14 %
  • -$11.85
  • IXIC
  • $18,439.17
  • 1.43 %
  • $259.19
Tarsus Pharmaceuticals, Inc. (TARS) Stock Price, News & Analysis

Tarsus Pharmaceuticals, Inc. (TARS) Stock Price, News & Analysis

Currency in USD Disclaimer

$45.66

-$0.55

(-1.19%)

Day's range
$43.77
Day's range
$47.05
50-day range
$25.82
Day's range
$48.6
  • Country: US
  • ISIN: US87650L1035
52 wk range
$15.47
Day's range
$48.6
  • CEO: Dr. Bobak R. Azamian M.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 7.04
  • Piotroski Score 2.00
  • Grade Outperform
  • Symbol (TARS)
  • Company Tarsus Pharmaceuticals, Inc.
  • Price $45.66
  • Changes Percentage (-1.19%)
  • Change -$0.55
  • Day Low $43.77
  • Day High $47.05
  • Year High $48.60

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/06/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $62.00
  • High Stock Price Target $63.00
  • Low Stock Price Target $61.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$4.75
  • Trailing P/E Ratio -6.78
  • Forward P/E Ratio -6.78
  • P/E Growth -6.78
  • Net Income $-135,893,000

Income Statement

Quarterly

Annual

Latest News of TARS

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.